Signals received at the cell surface must be properly transmitted to critical targets within the cell to achieve the appropriate biological response. This process of signal transduction is often initiated by receptor tyrosine kinases (RTKs), which function as entry points for many extracellular cues and play a critical role in recruiting the intracellular signaling cascades that orchestrate a particular response. Essential for most RTK-mediated signaling is the engagement and activation of the mitogenactivated protein kinase (MAPK) cascade comprised of the Raf, MEK and extracellular signal-regulated kinase (ERK) kinases. For many years, it was thought that signaling from RTKs to ERK occurred only at the plasma membrane and was mediated by a simple, linear Rasdependent pathway. However, the limitation of this model became apparent with the discovery that Ras and ERK can be activated at various intracellular compartments, and that RTKs can modulate Ras/ERK signaling from these sites. Moreover, ERK scaffolding proteins and signaling modulators have been identified that play critical roles in determining the strength, duration and location of RTK-mediated ERK signaling. Together, these factors contribute to the diversity of biological responses generated by RTK signaling.
Introduction
Receptor tyrosine kinases (RTKs) transmit signals that regulate cell proliferation and differentiation, promote cell migration and survival and modulate cellular metabolism. They play a critical role in a wide range of biological processes, including embryonic development, growth of an organism, angiogenesis, synaptic plasticity and oncogenesis. No longer considered a linear pipeline, RTK pathways are now viewed as intricate signaling networks, containing modules of multi-protein complexes that assemble at various intracellular compartments to process, integrate and transmit information that will ultimately specify a particular biological response. An essential effector cascade required for most RTK function is the mitogenactivated protein kinase (MAPK) cascade comprised of the Raf, MEK and extracellular signal-regulated kinase (ERK) kinases (known as the ERK cascade). Here, we will examine the signaling routes used by RTKs to mediate ERK activation (Figure 1) , and we will highlight recent studies that further elucidate the mechanisms regulating the activity and subcellular localization of various RTK/ERK pathway components. In addition, we will describe the ERK scaffolds and signaling modulators that contribute to RTK/ERK signaling.
RTK activation and the recruitment of enzymes, signaling adaptors and docking proteins RTKs are membrane-spanning, cell surface proteins that contain an N-terminal extracellular ligand binding domain and a C-terminal intracellular tyrosine kinase domain (reviewed in Schlessinger, 2000; Pawson, 2002) . Most RTKs exist as inactive monomers and form dimers following binding to their ligands, the vast majority of which are soluble peptides. Dimerization induces receptor activation and the autophosphorylation of tyrosine residues in the RTK intracellular domain that serve as specific binding sites for proteins that contain Src-homology 2 (SH2) or phosphotyrosine binding (PTB) domains. Proteins recruited to the activated RTK typically fall into two categories: enzymes whose activity is stimulated by the activated receptor (e.g., Src, PLCg, Shp-2 and PI3K) and adaptors that contain additional protein interaction motifs (e.g., Grb2 and Shc). Many activated RTKs also engage a third group of molecules collectively known as docking proteins (e.g., IRS, FRS and the Gab/Dok proteins). Docking proteins are often recruited to the RTK via an intrinsic PTB domain or through an interaction with the Grb2 adaptor. These proteins also contain a membrane targeting motif (either a pleckstrin homology (PH) domain or a myristoylation site) and multiple tyrosine phosphorylation sites that can interact with additional binding partners. Thus, through the receptor itself, adaptors and docking proteins, numerous signaling components are recruited to the cell surface, thereby activating the repertoire of effector cascades required for a specific response.
Ras activation at the plasma membrane
The Ras GTPase is the critical link that allows RTKs to signal to ERK. Activation of all RTKs stimulates the exchange of GTP for GDP on Ras, and this nucleotide exchange allows Ras to interact directly with its target effectors, one of which is the initiating kinase of the ERK cascade, Raf (Marshall, 1996) . The best-characterized route of Ras activation occurs at the plasma membrane and is mediated by the Sos guanine nucleotide exchange factor (Quilliam et al., 1995; Downward, 1996) . Sos is recruited from the cytosol to the plasma membrane as a result of its constitutive interaction with Grb2, whose SH2 domain can bind phosphotyrosine sites located on one or more of the following molecules: the activated RTK itself, Shc (another adaptor protein that binds activated RTKs via its PTB domain) or one of the membrane-localized docking proteins.
Placing Sos in the same locale as Ras was initially thought to be the primary mechanism regulating the Sos-mediated nucleotide exchange of Ras. However, subsequent structure-function studies have revealed that Sos exists in an autoinhibited state, and that interactions with Ras itself modulate Sos activity in a two-step manner. First, binding of RasGDP to an allosteric site on Sos that is distal to the catalytic site induces low GEF activity that generates RasGTP (Sondermann et al., 2004) . RasGTP then binds with higher affinity to the same site, fully relieving steric occlusion of the active site and inducing high GEF activity (Margarit et al., 2003; Freedman et al., 2006) . This regulatory mechanism not only ensures that cytosolic Sos is maintained in an inactive state, but also provides a positive feedback loop that has been recently shown to affect the duration, amplitude and output of Ras signaling in response to stimuli (Boykevisch et al., 2006) . Significantly, mutations of Sos that disrupt its autoinhibition have recently been identified in patients with Noonan's syndrome, a developmental disorder associated with dysregulation of the Ras/ERK pathway (Roberts et al., 2007; Tartaglia et al., 2007) .
Ras signaling from other intracellular compartments For many years, Ras activation was thought to occur exclusively at the plasma membrane. However, the isolation of active signaling complexes from endosomes that contain tyrosine-phosphorylated epidermal growth factor receptors, Grb2/Sos, Ras and Raf provided the first evidence that Ras might signal from other intracellular sites (Di Guglielmo et al., 1994; Baass et al., 1995) . More recently, studies utilizing new imaging technologies, such as fluorescence resonance energy transfer, have revealed that activated Ras proteins can be detected on various intracellular membranes, including the Golgi and endoplasmic reticulum as well as endosomes (Burke et al., 2001; Chiu et al., 2002; Jiang and Sorkin, 2002) . Interestingly, the kinetics of Ras activation differs at various intracellular sites, and evidence is now accumulating that compartmentalization may play an important role Figure 1 RTK to ERK signaling: Ras and ERK activation at various intracellular compartments. At the plasma membrane, activated RTKs promote Ras activation through the recruitment of Grb2/Sos complexes. KSR is an ERK scaffold that facilitates Rasdependent ERK cascade activation at the plasma membrane, whereas Paxillin directs ERK activation at focal adhesions. Active signaling complexes containing internalized receptors, Grb2/Sos and Ras are also found on endosomes. MP1 is an MEK1/ERK1-specific scaffold that localizes to late endosomes through an interaction with the adaptor protein p14. Activated RTKs can also direct the activation of Golgi-associated Ras through a signaling route involving Src, PLCg and RasGRP1. Sef is a Golgi-localized scaffold that recruits activated MEK and promotes ERK activation. Active ERK is retained on the Sef/MEK complex and confined to cytosolic substrates. The tyrosine phosphatase Shp-2 is another effector of RTKs that positively regulates Ras signaling by antagonizing the ability of negative regulators, such as CSK, RasGAP and Sprouty, to access and downregulate critical enzymes involved in Ras activation.
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in determining not only the strength, duration and targets of Ras signaling, but also the ultimate biological consequences of a signaling cue (Sorkin and Von Zastrow, 2002; Plowman and Hancock, 2005; Mor and Philips, 2006) . A major factor influencing Ras localization is the processing and trafficking of the different Ras family members, H-Ras, N-Ras and K-Ras. Membrane targeting of the various Ras proteins is determined by the sequence and post-translational modifications of their C-terminal regions known as the hypervariable region (HVR). Although all Ras proteins undergo farnesylation and carboxylmethylation, which localizes them to the endoplasmic reticulum (Choy et al., 1999) , their HVRs possess different secondary targeting motifs, which are required for stable plasma membrane association. The HVR of K-Ras 4B (the ubiquitous and predominant splice variant of K-Ras and referred to hereafter as K-Ras) contains a stretch of polybasic residues, whereas the HVRs of H-Ras and N-Ras contain cysteine residues that are palymitoylated (Hancock et al., 1990) . Processed K-Ras is confined primarily to the plasma membrane; however, when the polybasic region is phosphorylated or targeted by Ca 2 þ /calmodulin, K-Ras relocalizes to other endomembrane compartments, including the Golgi, endoplasmic reticulum and mitochondria (Fivaz and Meyer, 2005; Bivona et al., 2006) . In contrast, H-Ras and N-Ras constantly shuttle between the Golgi and plasma membrane as a result of a constitutive depalmitoylation/repalmitoylation cycle (Goodwin et al., 2005; Rocks et al., 2005) . Ubiquitination has recently been found to be another post-translation modification that distinguishes the Ras proteins and contributes to their intracellular localization (Jura et al., 2006) . The selective mono-and diubiquitination of H-Ras and N-Ras, but not K-Ras, is determined by their HVRs and requires farnesylation and palmitoylation. Ubiquitination of these Ras proteins stabilizes their association with endosomes and modulates their ability to interact with Raf and to activate the ERK cascade (Jura et al., 2006) .
In addition to regulating the classical Sos-mediated Ras exchange that occurs at the plasma membrane and on endosomes, RTKs can also direct the activation of Golgi-associated Ras through a signaling route that utilizes the RasGRP1 exchange factor (Bivona et al., 2003) . RasGRP1 is a C1-domain containing protein that is activated by diacylglycerol (DAG) and Ca 2 þ , in a manner analogous to members of the protein kinase C (PKC) family (Ebinu et al., 1998; Brose and Rosenmund, 2002) . Many activated RTKs induce the Srcdependent activation of PLCg, resulting in the production of DAG and an increase in intracellular Ca 2 þ . These second messengers then activate and direct RasGRP1 to the Golgi where it acts on Ras (Bivona et al., 2003) . Interestingly, studies of cell lines derived from Shp-2 knockout mice have revealed a role for the Shp-2 tyrosine phosphatase in Ras activation occurring at the Golgi (Zhang et al., 2004) . Shp-2 has long been known to be a positive regulator of RTK-mediated Ras activation and is a component of many activated RTK complexes, binding to either the receptor or an associated docking protein (Neel et al., 2003) . Shp-2 contributes to Ras signaling from the Golgi by stimulating the activation of Src family kinases, and in turn, their substrate PLCg (Zhang et al., 2004) . Shp-2 promotes Src activation by dephosphorylating binding sites on proteins that function to colocalize the inhibitory C-terminal Src kinase (CSK) with Src family members.
Shp-2 has also been reported to have positive effects on Ras signaling that occurs at the plasma membrane. First, by dephosphorylating binding sites on some receptors and docking proteins that mediate binding of the Ras GTPase activating protein (RasGAP), Shp-2 prevents the localization of RasGAP to the plasma membrane and thereby, prolongs Ras activation (Klinghoffer and Kazlauskas, 1995; Agazie and Hayman, 2003; Montagner et al., 2005) . Second, by dephosphorylating the negative signaling modulator Sprouty, Shp-2 prevents Sprouty from binding and blocking the membrane recruitment of Grb2/Sos (Hanafusa et al., 2004) . Thus, the general underlying mechanism for the positive effects exerted by Shp-2 on Ras signaling is that Shp-2 antagonizes the ability of negative regulators to access and downregulate critical enzymes involved in Ras activation.
The Ras/MEK/ERK cascade All activated Ras proteins can interact directly with the Raf family kinases (comprised of A-Raf, B-Raf and the most extensively studied C-Raf), and this interaction is a crucial first step required for Raf activation. Strikingly, converting the Raf kinases from inactive to active enzymes is a highly complex process, involving membrane localization, cycles of phosphorylation/dephosphorylation and protein interactions (Figure 2 ; reviewed in Dhillon and Kolch, 2002; Wellbrock et al., 2004) . All Raf proteins are thought to exist in an inactive state in the cytosol, with the N-terminal domain acting as an autoinhibitor of the C-terminal kinase domain. 14-3-3 dimers bind to phosphorylation sites present in both the N-and C-terminal regions, stabilizing the autoinhibited state and concealing the Nterminal Ras binding sites. RTK activation stimulates the membrane recruitment of Raf via Ras and induces the release of 14-3-3 from the N-terminal binding site, which together promote the phosphorylation of the kinase domain on activating sites. For the mammalian C-Raf and A-Raf proteins, these sites are located in two regions of the kinase domain -the negative-charge regulatory region (N-region) and the activation segment. In contrast, B-Raf appears to require only activation segment phosphorylation, given that its N-region exhibits a constitutive negative charge owing to increased basal phosphorylation of an activating serine site and the presence of two aspartic acid residues. The cumulative effect of these phosphorylation events as well as Ras binding and membrane lipid interactions is to disrupt the N-terminal autoinhibition and stabilize the active conformation of the kinase domain.
Despite the wealth of information that has been obtained regarding Raf activation, recent research reveals that there are still new details to be learned. In particular, the involvement of protein phosphatases (PPs) in the Raf activation process has been established. Both PP1 and PP2A have been shown to positively regulate Raf activity by dephosphorylating the inhibitory Raf N-terminal 14-3-3 binding site, thereby promoting the interaction with Ras and membrane recruitment (Abraham et al., 2000; Jaumot and Hancock, 2001; Ory et al., 2003; Rodriguez-Viciana et al., 2006) . Moreover, of particular interest are studies demonstrating that heterodimerization with B-Raf also contributes to C-Raf activation. Previously, it had been shown that Ras activation could induce the heterodimerization of B-Raf and C-Raf (Weber et al., 2001) . However, it was not until kinase-impaired, oncogenic B-Raf proteins were found to activate ERK through the binding and transactivation of C-Raf that the significance of Raf heterodimerization was fully appreciated (Wan et al., 2004) . More recently, biochemical analysis of Raf heterodimers together with RNA interference studies has shown that heterodimerization with B-Raf also contributes to C-Raf activation in response to normal signaling events (Garnett et al., 2005; Rushworth et al., 2006) . Heterodimerization with B-Raf is thought to induce the 'active' kinase conformation of C-Raf, in a manner that requires phosphorylation of the C-Raf activation segment (Garnett et al., 2005) . Whether B-Raf directly phosphorylates C-Raf, recruits another kinase or induces C-Raf to autophosphorylate is unknown. Oncogenic B-Raf proteins interact constitutively with C-Raf in a Ras-independent manner, whereas binding between wild-type B-Raf and C-Raf is induced by Ras activation (Garnett et al., 2005) . In either case, however, 14-3-3 appears to mediate the interaction, as mutation of the C-terminal 14-3-3 binding site on C-Raf disrupts the B-Raf/C-Raf complex (Weber et al., 2001; Garnett et al., 2005; Rushworth et al., 2006) . It is yet to be determined whether C-Raf can modulate B-Raf activity and whether heterodimerization extends to the A-Raf kinase. In addition, although active Ras proteins are localized to various intracellular compartments, it is not clear whether the Raf activation process is the same at each site or whether some Raf family members play a more specialized role in Ras signaling from certain intracellular compartments.
Once activated, all Raf family members are capable of initiating the phosphorylation cascade, whereby Raf activates MEK, and MEK in turn activates ERK. However, in contrast to the complexity observed in Raf activation, MEK and ERK become fully activated simply through the phosphorylation of the activation segments in their respective kinase domains (Payne et al., 1991; Alessi et al., 1994; Mansour et al., 1994; Zheng and Guan, 1994) . The ultimate goal of RTK to ERK signaling is then achieved when active ERK phosphorylates critical targets in the cytoplasm and nucleus required to carry out the cellular response specified by the initiating signal.
ERK scaffolds involved in RTK signaling MAPK scaffolds are now recognized to play an important role in mammalian signal transduction (Morrison and Davis, 2003; Kolch, 2005) . These proteins act as docking platforms that colocalize the kinase components of a particular MAPK cascade and Figure 2 Membrane recruitment of Raf and KSR. 'Inactive': 14-3-3 dimers bind and retain inactive B-Raf and C-Raf proteins in the cytosol. The inactive KSR1 scaffold constitutively interacts with MEK, CK2 and the catalytic subunits of PP2A, and is sequestered from the plasma membrane by interactions with 14-3-3 and IMP. 'Active': C-Raf and B-Raf are recruited to the plasma membrane as a result of RasGTP binding and the dephosphorylation of N-terminal 14-3-3-binding sites, mediated by either PP1 or PP2A. Raf proteins are activated at the membrane through a complex process that involves phosphorylation events and protein/lipid interactions. Heterodimerization with B-Raf also contributes to C-Raf activation and requires the binding of 14-3-3 to the C-terminal Raf sites. Ras activation also mediates the translocation of the KSR1 scaffold to the plasma membrane. RasGTP disrupts the IMP/KSR1 interaction by recruiting IMP to the cell surface and promoting its autoubiquitination. Ras activation also induces binding of the PP2A regulatory B subunit to the KSR1-associated PP2A catalytic core complex. B subunit binding stimulates the dephosphorylation and release of 14-3-3 from one of the KSR1 sites, thereby unmasking the C1 domain required for membrane targeting as well as the ERK docking site. At the plasma membrane, KSR1 interacts with Raf and in doing so colocalizes the Raf kinases with MEK and ERK. In addition, KSR1 brings the active CK2 holoenzyme, which can function as a Raf family N-region kinase.
facilitate MAPK activation. Moreover, they provide specificity to MAPK signaling by insulating the module from irrelevant stimuli and by regulating the module's subcellular localization. Proteins that contribute to the spatiotemporal activation of ERK in RTK pathways are kinase suppressor of Ras 1 (KSR1), MEK-partner 1 (MP1), Sef and Paxillin (Figure 3 ). An emerging feature of these ERK scaffolds is that through their distinct subcellular localizations, they contribute to the compartmentalization of Ras/ERK signaling (Figure 1 ).
KSR. KSR is a multi-domain scaffold that interacts with Raf, MEK and ERK and facilitates ERK activation at the plasma membrane. KSR was identified genetically in flies and worms as a positive regulator of Ras/ERK signaling, and two family members (KSR1 and KSR2) are found in mammals. Like the Raf kinases, the localization of mammalian KSR1 is dynamic and controlled by a variety of protein interactions and phosphorylation/dephosphorylation events ( Figure 2) . In quiescent cells, KSR1 is sequestered from the plasma membrane by interactions with a 14-3-3 dimer and impedes mitogenic signal propagation (IMP), an E3 ubiquitin ligase. The phosphorylation-dependent binding of 14-3-3 retains KSR1 in the cytosol by masking the cysteine-rich C1 domain required for membrane targeting (Muller et al., 2001) , and when bound to IMP, KSR1 mislocalizes to a detergentinsoluble cellular compartment (Matheny et al., 2004) . KSR1 also constitutively interacts with MEK1/2, the core catalytic subunits of PP2A, and the serine/ threonine kinases C-TAK1 and CK2 (Denouel-Galy et al., 1998; Yu et al., 1998; Muller et al., 2001; Ory et al., 2003; Ritt et al., 2007) . RTK signaling induces the translocation of KSR1 to the plasma membrane by promoting the exposure of the KSR1 C1 domain and by freeing KSR1 from IMP. Specifically, the IMP/KSR1 interaction is disrupted by activated Ras, which binds directly to IMP and promotes its autoubiquitination (Matheny et al., 2004) . Ras activation also causes the PP2A regulatory B subunit to bind the KSR1-associated PP2A catalytic core complex (Ory et al., 2003) , forming a complete holoenzyme that catalyses the dephosphorylation of one of the KSR1 14-3-3 binding sites. The release of 14-3-3 from this site exposes the membranetargeting C1 domain (Zhou et al., 2002) , as well as the docking site for ERK1/2 (Jacobs et al., 1999) . At the plasma membrane, KSR1 interacts with Raf and in doing so colocalizes MEK and ERK with their upstream activator. KSR1 also transports the active CK2 holoenzyme, which can contribute to Raf activation by functioning as a Raf N-region kinase (Ritt et al., 2007) . Interestingly, of the ERK scaffolds utilized by RTKs, KSR1 is the only one whose localization changes in response to signal activation.
MP1. MP1 is a small ERK scaffold that localizes to late endosomes and selectively promotes the activation of ERK1. MP1 was identified in a two-hybrid screen for MEK1-binding partners and interacts with MEK1 and ERK1, but not MEK2 or ERK2. MP1 localizes to late endosomes through a constitutive interaction with p14, a highly conserved adaptor protein that resides on the cytoplasmic face of endosomes (Wunderlich et al., 2001) . Protein depletion studies using RNAi have shown that the endosomal localization of the p14/MP1 complex is required for full ERK activation in response to EGF stimulation (Teis et al., 2002) . Interestingly, however, loss or mislocalization of the p14/MP1 complex was found to have no significant effect on the early activation of ERK at the plasma membrane, but it did alter the sustained ERK activation seen on endosomes. More recently, conditional disruption of p14 in mice has been found to impair late endosomal trafficking as well as endosomal ERK activation, resulting in cell proliferation defects that disrupt early embryogenesis and tissue homeostasis (Teis et al., 2006) . In addition, a causal link has recently been revealed between p14 deficiency and a novel human immunodeficiency syndrome associated with aberrant endosomallysosomal function (Bohn et al., 2007) . Together, these findings demonstrate the importance of endosomal Paxillin. Paxillin is an integral component of focal adhesion complexes and is a scaffold that directs ERK activation at sites of focal adhesions (Ishibe et al., 2003) . Paxillin interacts constitutively with MEK and, in response to activation of the hepatocyte growth factor receptor (HGFR), also binds activated Raf and inactive ERK. Interestingly, the binding of inactive ERK is dependent on the Src-dependent phosphorylation of paxillin at Y118. Once bound and activated, ERK then phosphorylates paxillin on S83, which promotes binding of focal adhesion kinase (FAK) and, in turn, activation of PI3K and Rac. Analysis of paxillin mutants defective either in ERK binding or ERK-mediated phosphorylation indicates that the localization of active ERK to focal adhesions is critical for the turnover of focal adhesion complexes and the initiation of epithelial morphogenesis (Ishibe et al., 2004) .
Modulators of RTK to ERK signaling
Because diverse extracellular cues are transduced through the RTK/Ras/ERK cascade, qualitative differences in properties such as duration and amplitude of the ERK signal are important for achieving the appropriate biological response. These aspects of ERK signaling are influenced by signaling modulators that have been identified and found to augment the efficiency and level of ERK signaling, provide regulated inhibition and/or mediate crosstalk with other signaling cascades (Figure 3 ).
Positive modulators: Sur-8 and CNK. Two proteins identified by genetic studies as positive regulators of RTK/Ras-mediated ERK activation are suppressor of ras-8 (Sur-8) and connector enhancer of KSR (CNK). Sur-8 is a leucine-rich repeat protein, and initial studies characterizing mammalian Sur-8 found that when overexpressed, Sur-8 could enhance Raf activation by promoting the Ras/Raf interaction (Li et al., 2000) . More recently, Sur-8 has been reported to function as a regulatory protein for the catalytic subunit of PP1, and through an interaction with M-Ras (a relative of the prototypical H-, N-and K-Ras proteins), contributes to the Raf activation process by promoting the dephosphorylation of the inhibitory N-terminal 14-3-3 binding site on Raf (Rodriguez-Viciana et al., 2006) . These findings have led to the model that Sur-8 acts to enhance the strength of ERK signaling by facilitating events that promote Raf activation. Multiple CNK proteins (CNK1, CNK2A, CNK2B, CNK2C and CNK3) are found in mammals and they possess known protein interaction domains including a sterile a motif, a conserved region in CNK domain, a PDZ domain and a PH domain. The most ubiquitously expressed mammalian CNK protein, CNK1, has been reported to augment C-Raf activation by colocalizing the Src tyrosine kinase with membrane-localized C-Raf, thereby promoting the phosphorylation of the C-Raf Nregion by Src (Ziogas et al., 2005) . CNK1 has also been found to interact with various Ral and Rho pathway components and to influence Rho-mediated gene transcription and activation of the JNK/MAPK pathway (Jaffe et al., 2004 (Jaffe et al., , 2005 . To date, studies examining the mammalian CNKs suggest that these proteins have multiple functions, facilitating ERK cascade activation as well as mediating crosstalk between various effector cascades.
Negative modulators: Erbin, Sprouty/SPRED and RKIP. Negative modulators that specifically antagonize RTK-and Ras-mediated signaling have also been identified and include Erbin, Sprouty, Sprouty-related proteins with EVH1 domains (SPRED) and Raf kinase inhibitor protein (RKIP). Erbin is a member of the LAP (leucine rich-repeat and PDZ domain) protein family that interacts with Ras and precludes the binding of Raf to activated Ras (Huang et al., 2003; Dai et al., 2006) . The Sprouty proteins can inhibit, in a context-dependent manner, ERK signaling by binding and sequestering the Grb/Sos complex, thus preventing Ras activation (Hanafusa et al., 2002) . In addition, both the Sprouty and SPRED proteins can interact with the Raf catalytic domain and, depending on the biological context, interfere with the phosphorylation of Raf on activating sites (Wakioka et al., 2001; Sasaki et al., 2003) . RKIP interacts with the kinase domain of both MEK and Raf and prevents the Raf/MEK interaction (Yeung et al., 2000) . A common feature for these proteins is that they all interfere with critical protein interactions involved in RTK to ERK signaling.
Concluding comments
The past two decades have witnessed tremendous advances in our understanding of how RTKs mediate ERK activation. Following the initial discoveries of the individual core components of the pathway, such as RTKs, Ras, Raf, MEK and ERK, many years of study were devoted to the elucidation of their biochemical activities and their relationships within the cascade. The accelerating pace of research in recent years has revealed that RTK to ERK signaling can occur at other intracellular compartments in addition to the plasma membrane, and that numerous auxiliary factors, such as ERK scaffolding proteins and signaling modulators, play key roles in determining the strength, duration and location of ERK signaling. Although much remains to be clarified, it has already become apparent that RTK to ERK signaling is controlled by highly dynamic and complex regulatory mechanisms. Elucidating the details of these events and how ERK signaling from various compartments integrates with other RTK effector cascades will be crucial in understanding how this important pathway mediates such diverse cellular responses. Moreover, because aberrant RTK to ERK signaling has been implicated in a variety of human diseases, including cancer, further identification of proteins and mechanisms regulating this signaling process may reveal novel targets for therapeutic intervention.
